Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The Grand Plan Study showed that a multidisciplinary program can produce a high cure rate with little loss to follow-up.
Greater political will and financial support for national programs are needed to eliminate viral hepatitis.
The three-drug combination cured most people who had experienced previous treatment failure.
Among people with fatty liver disease, those with diabetes were more likely to advance by one fibrosis stage in less than six years.
ReLink programs treated 19% of people who were brought back into HCV care after being lost to follow-up.
Positive results announced by Madrigal Pharmaceuticals could potentially lead to the first drug approval for fatty liver disease.
Women and young adults saw especially large increases between 2019 and 2021.
As new cases of acute hepatitis among kids have declined, questions remain unanswered.
Even without HBV immunoglobulin, no infants acquired hepatitis B from mothers with a high viral load.
Black people make up only 6% and Latino people make up 5% of participants in cirrhosis trials in the United States.
Two thirds of people who currently use drugs completed treatment, and most of those were cured.
People who achieved SVR two or more years ago were less likely to develop hepatocellular carcinoma than those cured more recently.
People who recently used drugs were more likely to get HCV again after successful treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.